Member of the British Society for Haematology General Haematology Task Force
2024 - 2027
Professor David Allsup's Recognition (58)
Medical advsior to NICE
2024 - 2024
Description Medical advisor to NHS and NICE in relation to assessment of medical technologies for haemophilia treatment Affiliated Organisations Hull University Teaching Hospitals NHS Trust
CLL, diagnosis, treatment pathways and research
2024 - 2024
Description Plenary podium lecture at the CLL support association annual conference. A meeting to support persons diagnosed with CLL. Projects STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL) Org Units Centre for Biomedicine URL https://cllsupport.org.uk/conference-reports/york-conference/
Management of acute leukaemia and pregnancy outcomes in patients with current or previous leukaemia
2024 - 2024
Description Management of acute leukaemia and pregnancy outcomes in patients with current or previous leukaemia
Dr Lukas Pitel, Dr Matthew Northgraves, Prof. Judith Cohen, Dr Chao Huang, Mr. John Turgoose, Dr Sahra Ali, Prof. Mhairi Copland, Panagiotis D. Kottaridis, Dr David Allsup
ePoster presentation at British Society for Haematology Meeting Liverpool, April 2024.Projects LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy Org Units Centre for Biomedicine URL https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.19399
A single centre assessment of the frequency and clinical relevance of discrepant factor VIII assays both in persons without a disorder of haemostasis and in those with haemophilia A
2024 - 2024
Description Lead author on poster presentation at European Society for Haemophilia and Allied Disorders Meeting, Frankfurt, February 2024. Affiliated Organisations Hull York Medical School
Interim Analysis of Real-World Effectiveness and Usage of Recombinant Factor IX Fc for Surgical Haemostasis from the 24-Month Prospective, Non-Interventional B-MORE Study
2024 - 2024
Description Coauthor on poster presentation at European Association for Haemophilia and Allied Disorders Meeting Frankfurt February 2024. Affiliated Organisations Hull York Medical School
Does the Life Expectancy of Elderly CLL patients receiving upfront Targeted Agents approach the Life Expectancy of the General Population?
2023 - 2023
Description Oral presentation at the International Workshop in CLL, Boston, USA. Affiliated Organisations University of Hull Research Centres/Groups Aura Innovation Centre
Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment.
2023 - 2023
Description Co-author on the above oral presentation at the International Workshop for CLL, Boston, USA. Affiliated Organisations University of Hull
Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: Report of the Phase III UK NCRI FLAIR study
2023 - 2023
Description Co-author on the above oral presentation at the Amercian Society Haematology, San Diego, December 2023. Affiliated Organisations University of Hull
Using peripheral blood (PB) measurable residual disease (MRD) levels to predict <0.01% bone marrow disease (BM uMRD4): identification of effective PB targets for CLL treatment cessation in the ibrutinib+venetoclax arm of the FLAIR trial
2023 - 2023
Description Co-author on the above presentation at the American Society of Haematology meeting, San Diego, USA, December 2023. Affiliated Organisations University of Hull
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients in FLAIR Study with previously untreated chronic lymphocytic leukaemia: Assessment of mutational landscape of patients at baseline and prognostic impact
2023 - 2023
Description Co-author on above poster presentation at the American Society of Haematology Meeting San Diego USA, December 2023. Affiliated Organisations University of Hull
Targeted Agents in CLL: Advancements in Overall Survival Outcomes?
2023 - 2023
Description Co-author on the above poster presentation at the American Society of Haematology Meeting, San Diego USA, December 2023. Affiliated Organisations University of Hull
Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact
2023 - 2023
Description Co-author on the above conference presentation ,poster, at the American Society of Haematology meeting, San Diego, USA, December 2023. Affiliated Organisations University of Hull
Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
2022 - 2022
Description Conference presentation American Society of Haematology 2022 Affiliated Organisations Hull York Medical School Projects CLL Research
Sudden or Cardiac Deaths on Ibrutinib-Based Therapy were associated with a prior History of Hypertension or Cardiac Disease and the use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
2022 - 2022
Description Conference presentation British Society for Haematology, 2022 Affiliated Organisations Hull York Medical School
THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
2022 - 2022
Description Conference presentation European Haematology Association Congress Affiliated Organisations Hull York Medical School
Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
2022 - 2022
Description Conference presentation American Society of Haematology, 2022 Affiliated Organisations Hull York Medical School
The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis
2022 - 2022
Description Conference presentation American Society of Haematology 2022 Affiliated Organisations Hull York Medical School Projects CLL Research
Biomarker Driven Antifungal Stewardship in Acute Leukaemia (BioDriveAFS)—a multicentre randomized controlled trial to assess clinical and cost effectiveness
2022 - 2022
Description Conference presentation, BSAC meeting, London 2022. Affiliated Organisations Hull York Medical School Projects The Biomarker Driven Antifungal Stewardship in AML: The BioDriveAFS Trial
Member of Trial Managment Group for STATIC clinical trial
2022 - 2030
Affiliated Organisations Hull York Medical School Projects STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)